<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="326">
  <stage>Registered</stage>
  <submitdate>30/08/2005</submitdate>
  <approvaldate>6/09/2005</approvaldate>
  <actrnumber>ACTRN12605000318684</actrnumber>
  <trial_identification>
    <studytitle>Macrolide treatment of Non-Eosinophilic Asthma</studytitle>
    <scientifictitle>A double blind randomised controlled study of the anti-inflammatory effects of clarithromycin 500mg twice daily for 8 weeks in adults with symptomatic Non-Eosinophilic Asthma</scientifictitle>
    <utrn />
    <trialacronym>NEAT</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Clarithromycin 500mg twice daily for 8 weeks</interventions>
    <comparator>Placebo (calcium carbonate)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>IL-8 concentations in sputum supernatant</outcome>
      <timepoint>Assessed at randomisation and at the end of the treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>MMP-9 concentations in sputum supernatant</outcome>
      <timepoint>Assessed at randomisation and at the end of the treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>FEV1% predicted</outcome>
      <timepoint>Assessed at randomisation and at the end of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Short acting beta agonist use</outcome>
      <timepoint>Assessed at randomisation and at the end of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Asthma Control Score</outcome>
      <timepoint>Assessed at randomisation and at the end of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>Assessed at randomisation and at the end of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Symptomatic stable asthma, airway hyperresponsiveness and or bronchodilator response.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hypersensitivity to Macrolides, Other Respiratory Disease, Taking antihistamine medication, Pregnancy, Breast Feeding, Oral Corticosteroid use in past month, Antibiotic use in past month.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomised by pharmacy using random number list, concealed from investigators by identical capsules and non-identifying labelling</concealment>
    <sequence>Permuted blocks. Random allocation was generated using web based software www.randomization.com</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Hunter New England Area Health Service</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Newcastle</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Peter G Gibson</name>
      <address>Respiratory and Sleep Medicine
Hunter Medical Research Institute
Level 3
John Hunter Hospital
Locked Bag 1
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 49855766</phone>
      <fax>+61 2 49855850</fax>
      <email>peter.gibson@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jodie L Simpson</name>
      <address>Respiratory and Sleep Medicine
Hunter Medical Research Institute
Level 3
John Hunter Hospital
Locked Bag 1
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 49214965</phone>
      <fax>+61 2 49855850</fax>
      <email>jodie.simpson@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>